- Table of Contents
We validate the specificity of these antibodies to PRKAA1 by testing them on tissues known to express PRKAA1 positively and negatively. Browse below to find the PRKAA1 antibody that suites your experiment. We have 20 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about 5'-AMP-activated protein kinase catalytic subunit alpha-1.
AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin.
|protein kinase superfamily|
AMP -activate kinase alpha 1 subunit; AMP-activated protein kinase, catalytic, alpha-1,5'-AMP-activated protein kinase catalytic subunit alpha-1; AMPK alpha 1; AMPK alpha 1,5'-AMP-activated protein kinase, catalytic alpha-1 chain; AMPK subunit alpha-1; AMPK; AMPK1; AMPKa1; EC 2.7.11; EC 126.96.36.199; MGC33776; MGC57364; PRKAA1; protein kinase, AMP-activated, alpha 1 catalytic subunit
|Sequence:||5; NC_000005.10 (40759379..40798195, complement)|
Cytoplasm. Nucleus. In response to stress, recruited by p53/TP53 to specific promoters.
This article will discuss the numerous benefits of the PRKAA1 marker in a variety of applications. By using this antibody, you can perform experiments analyzing lineage and cell type expression, including gene mapping and RNA-seq. We will also talk about the development and use of secondary antibodies as well as ELISA kit kits. For more information, visit Boster Bio. This product is available in the Picoband(tm) catalog.
FITC-labeled antibody against specific cell lineage markers are available from Agilent. These monoclonal antibodies are compatible with the majority of flow cytometers. the single-color conjugates contain an array of high-quality conjugated antibodies. Agilent also offers kits and control reagents with accessories which can be used with flow cytometry.
FITC-labeled antigens against human lineage markers were used to separate Treg cells from normal mice or animals treated. The FITC-labeled antigen was used to determine the presence of lineage markers in human stem cells. These antibodies were obtained from peripheral blood. They were then washed with PBS and suspended in 0.1% BSA. Then they were incubated in anti-CD97 or anti-CD11c antibodies. After sorting and testing the viability of samples was determined at 0 and 24 hours intervals.
To double-labeled anti-cell lineage markers FITC-labeled antibodies were used against CD34 and Flt-1. The cells were then processed through flow cytometry. Similar procedures were used to make FITC-labeled antibodies against human KDR. These antibodies against these cell lines have been shown to show high specificity and therefore are useful in studies of cell differentiation.
FITC-labeled human monocytes-specific antibodies have been utilized in studies to track cell differentiation and disease progression. Monocytes that are FITC-labeled express Flt-1, a transmembrane receptor-type molecule that may serve as a marker of lineage for monocyte macrophage cells. There are other FITC-labeled antibodies for monocyte-macrophage differentiation, including human lymphocyte-progenitor cells and human lymphocyte-regenerative diseases.
The PRKAA1 gene is more prominently expressed in gastric cancer than normal stomach tissue. The expression of PRKAA1 has been reduced in breast cancer, esophageal carcinoma squamous-cell carcinoma, and breast cancer. In addition to gastric cancer it is also expressed in other cancers. In a recent study, it was discovered that PRKAA1 is present in both gastric cancer as well as the esophageal squamous-cell carcinoma.
The PRKAA1 gene that is activated is a key gene in cancer research. It plays a variety of functions in the growth of cells and metabolism. It can affect the cell cycle as well as autophagy. Normal cells have an AMP/ATP ratio that is balanced. However, an imbalanced ratio of AMP/ATP can be linked to a variety of illnesses. It is possible that PRKAA1 activates AMPK, which may also affect the checkpoint of cell cycle G1/S arrest.
Studies that examined the connection between the PRKAA1 gene polymorphism and chance of developing cancer were included in the meta-analysis. The meta-analysis also assessed the quality of clinical studies that were accepted and excluded those of poor quality. The study data were classified by ethnicity, cancer type, as well as the source of control. Then, Bonferroni corrections were used to adjust the P value of the Z statistic, a statistical test used to reduce false-positive results.
The composite marker combines three distinct FISH markers that are LAMP3, PROX1 and PRKAA1. The percentages of cells with amplified signals for the individual markers were used to determine the best threshold for the composite marker. The composite marker produced the borderline of significance (P = 0.052). The highest positive scores had ratios of less than zero. This marker can be used to predict metastases and may also be useful as diagnostic tools.
The process of immunizing a person with an antigen that is specific to it, known as PRKAA1 can be used to produce secondary antibodies. The animal of the host is typically mouse, but other species could be used. The goat, donkey, and rabbit are the most frequently used, but other species may be used. The PRKAA1 marker is located on the CD4-receptor of mouse cells.
Primary antibodies were made by incubating the lysates of Prkaa1-deficient and wild type BMDMs in RIPA lysis buffer. The buffer also contained phosphatase inhibitors and protease (Roche). The cells were then subjected the process of centrifugation, sonication and Blotting.
B cells that are activated express various markers of the Prkaa1 antigen. Interestingly, Prkaa1-deficient mice showed reduced MBC surface markers when compared to wild-type controls. It is possible that Prkaa1 deficient mice show diminished MBC formation. Prkaa1 deficient mice could also have issues with the production of GCs or recall-induced antibodies.
Designing ELISA kits using the PRKAA1 marker can be challenging, especially if you are not an expert in biochemical techniques. This method employs high-affinity antibodies that detect a target protein. They can also eliminate binding materials that are not specific to. In a simple preparation it is efficient in measuring specific levels of antigen. The process can also be carried out in a cost-effective way, since Creative Diagnostics' highly qualified staff of scientists is prepared to collaborate with your company.
An ELISA kit that utilizes PRKAA1 markers requires the use of a sample of serum. The serum is subjected to a reaction that is mediated by the enzyme. The color of the substrate will change following the reaction. The intensity of the color reflects the level of enzyme present in the sample. The presence of a substance such as HRP is the catalyst for the reaction. The process stops when the enzyme has reached its highest concentration.
The PRKAA1 marker can be used to identify PRK antibodies in bloodstream. Developing ELISA kits to detect PRK antibodies requires the optimization of the conditions for coating plates and also the immobilization strategy and antigens. An ELISA solid phase is comprised of a 96/384 well plate of polystyrene or other suitable materials.
An ELISA kit is developed with a variety of blockers. These blockers come with different levels of nonspecific binding and the choice of the appropriate one is based on a variety of factors. The most crucial aspect to consider when selecting a blocker is the signal to noise ratio. The wrong blocker can create an excessive background that obscures the signal of the interaction between the antibody and antigen. A poor choice of a blocking agent could result in side effects or block enzyme activity.
ELISAs are commonly performed using either direct capture or sandwich capture. The capture process involves immobilizing the antigen onto the surface of the plate, while the detection procedure involves the use of pre-coated antibody. The most popular sandwich ELISA method can detect the presence of a target antibody. The sensitivity of the test is determined by the specificity of the antigen targeted.
*More publications can be found for each product on its corresponding product page